Insider Trading History of Valenzano Ken

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Valenzano Ken since 2011. The trader's CIK number is 1492123. At the time of the last reporting, Valenzano Ken was the VP, Pharmacology & Biology of Amicus Therapeutics, Inc.. (stock ticker symbol FOLD). Also see all insider trading activities at Amicus Therapeutics, Inc..


Yearly summary of insider trading at Amicus Therapeutics, Inc. (FOLD) by Valenzano Ken

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2015 FOLD 0 $0 74,301 $955,192 84,593 $792,570
2014 FOLD 44,450 $312,500 44,450 $312,500 0 $0
2011 FOLD 0 $0 2,250 $16,875 2,250 $1,435


Insider trading of Amicus Therapeutics, Inc. (FOLD) by Valenzano Ken

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2015-07-13 FOLD Option Ex 15,000 15.00 225,000
2015-07-13 FOLD Sale 15,000 15.00 225,000
2015-06-22 FOLD Option Ex 20,500 13.85 284,007
2015-06-22 FOLD Sale 20,500 13.85 284,007
2015-05-11 FOLD Sale 13,000 10.85 140,998
2015-05-08 FOLD Option Ex 25,000 .00 0
2015-04-15 FOLD Option Ex 5,000 12.50 62,500
2015-04-15 FOLD Sale 5,000 12.50 62,500
2015-03-20 FOLD Option Ex 6,043 11.68 70,558
2015-03-20 FOLD Sale 7,751 11.89 92,182
2015-03-20 FOLD Option Ex 13,050 11.53 150,505
2015-03-20 FOLD Sale 13,050 11.53 150,505
2014-11-25 FOLD Buy 25,000 8.00 200,000
2014-11-25 FOLD Sale 25,000 8.00 200,000
2014-08-25 FOLD Sale 12,450 6.00 74,700
2014-08-25 FOLD Buy 12,450 6.00 74,700
2014-08-20 FOLD Buy 7,000 5.40 37,800
2014-08-20 FOLD Sale 7,000 5.40 37,800
2011-05-24 FOLD Option Ex 2,250 .64 1,435
2011-05-24 FOLD Sale 2,250 7.50 16,875

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Valenzano Ken (VP, Pharmacology & Biology of Amicus Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.